Abstract:Schematic diagram illustrating the mechanism by which PYCR1 knockout/inhibition hinders liver cancer (LC) progression by regulating IRS1 expression through lactylation. Upon PYCR1 knockout/inhibition, LC glycolysis is inhibited, and the intracellular lactate level decreases. As a result, the enrichment of H3K18la in the promoter region of IRS1 is lost, leading to a reduction in IRS1 expression. Immediately afterward, the downstream activation of the PI3K/AKT/mTOR and MAPK/ERK pathways was weakened, resulting in a failure to promote the growth and metastasis of LC cells. Background Liver cancer (LC) is among the deadliest cancers worldwide, with existing treatments showing limited efficacy. This study aimed to elucidate the role and underlying mechanisms of pyrroline‐5‐carboxylate reductase 1 (PYCR1) as a potential therapeutic target in LC. Methods Immunohistochemistry and Western blot were used to analyse the expression of PYCR1 in LC cells and tissues. EdU assays, colony‐forming assays, scratch wound healing assays, Transwell assays, nude mouse xenograft models and nude mouse lung metastasis models were used to detect the growth and metastasis abilities of LC cells. Transcriptome sequencing was used to search for downstream target genes regulated by PYCR1, and metabolomics was used to identify the downstream metabolites regulated by PYCR1. ChIP assays were used to analyse the enrichment of H3K18 lactylation in the IRS1 promoter region. Results We found that the expression of PYCR1 was significantly increased in HCC and that this high expression was associated with poor prognosis in HCC patients. Knockout or inhibition of PYCR1 inhibited HCC cell proliferation, migration and invasion both in vivo and in vitro. In addition, we revealed that knocking out or inhibiting PYCR1 could inhibit glycolysis in HCC cells and reduce H3K18 lactylation of the IRS1 histone, thereby inhibiting IRS1 expression. Conclusions Our findings identify PYCR1 as a pivotal regulator of LC progression that influences tumour cell metabolism and gene expression. By demonstrating the potential of targeting PYCR1 to inhibit LC cell proliferation and metastasis, this study identified PYCR1 as a promising therapeutic target for LC. Highlights Pyrroline‐5‐carboxylate reductase 1 (PYCR1) promotes the proliferation and metastasis of liver cancer (LC) cells. The expression of PYCR1 in LC is regulated by DNA methylation. Knocking down or inhibiting PYCR1 inhibits glycolysis as well as the PI3K/AKT/mTOR and MAPK/ERK pathways in LC cells. PYCR1 regulates the transcriptional activity of IRS1 by affecting H3K18 lactylation in its promoter region.

PYCR1 regulates TRAIL‐resistance in non‐small cell lung cancer cells by regulating the redistribution of death receptors

Pyrroline-5-carboxylate Reductase 1 Promotes Proliferation and Inhibits Apoptosis in Non-Small Cell Lung Cancer

Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers

PYCR1 Promotes the Malignant Progression of Lung Cancer Through the JAK-STAT3 Signaling Pathway Via PRODH-dependent Glutamine Synthesize

Pyrroline-5-carboxylate Reductase 1 (PYCR1) Upregulation Contributes to Gastric Cancer Progression and Indicates Poor Survival Outcome

Effects of PYCR1 on Prognosis and Immunotherapy Plus Tyrosine Kinase Inhibition Responsiveness in Metastatic Renal Cell Carcinoma Patients

Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma

Knockdown of PYCR1 Inhibits Proliferation, Drug Resistance and EMT in Colorectal Cancer Cells by Regulating STAT3-Mediated P38 MAPK and NF-κB Signalling Pathway.

PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma

ERK1/2-mediated Cytoplasmic Accumulation of Hnrnpk Antagonizes TRAIL-induced Apoptosis Through Upregulation of XIAP in H1299 Cells.

PYCR1 promotes liver cancer cell growth and metastasis by regulating IRS1 expression through lactylation modification

Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3.

Hnrnpk Inhibits GSK3β Ser9 Phosphorylation, Thereby Stabilizing C-Flip and Contributes to TRAIL Resistance in H1299 Lung Adenocarcinoma Cells

The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer

Deciphering the Effects of the PYCR Family on Cell Function, Prognostic Value, Immune Infiltration in ccRCC and Pan-Cancer

CRIF1 Promotes the Progression of Non-Small-cell Lung Cancer by SIRT3- Mediated Deacetylation of PYCR1.

Redistribution of DR4 and DR5 in Lipid Rafts Accounts for the Sensitivity to TRAIL in NSCLC Cells

Absence of Death Receptor Translocation into Lipid Rafts in Acquired TRAIL-resistant NSCLC Cells.

PKCα–GSK3β–NF-κB Signaling Pathway and the Possible Involvement of TRIM21 in TRAIL-induced Apoptosis

Novel Molecular Regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail)-Induced Apoptosis in NSCLC Cells